Cited by 1,155Multiple Myeloma Research and TreatmentsBone health and treatmentsMultiple Sclerosis Research Studies

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Open access

Attal, Michel, Lauwers-Cances, Valerie, Marit, Gerald, Caillot, Denis, Moreau, Philippe, Facon, Thierry, Stoppa, Anne Marie, Hulin, Cyrille, Benboubker, Lofti, Garderet, Laurent, Decaux, Olivier, Leyvraz, Serge, Vekemans, Marie-Christiane, Voillat, Laurent, Michallet, Mauricette, Pegourie, Brigitte, Dumontet, Charles, Roussel, Murielle, Leleu, Xavier, Mathiot, Claire, Payen, Catherine, Avet-Loiseau, Hervé, Harousseau, Jean-Luc·2012·New England Journal of Medicine

DOI 10.1056/nejmoa1114138

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: High-dose chemotherapy with autologous stem-cell transplantation is a standard treatment for young patients with multiple myeloma. Residual disease is almost always present after transplantation and is responsible for relapse. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide maintenance therapy after transplantation. METHODS: We randomly assigned 614 patients younger than 65 years of age who had nonprogressive disease after first-line transplantation to maintenance treatment with either lenalidomide (10 mg per day for the first 3 months, increased to 15 mg if tolerated) or placebo until relapse. The primary end point was progression-free survival. RESULTS: Lenalidomide maintenance therapy improved median progression-free survival (41 months, vs. 23 months with placebo; hazard ratio, 0.50; P<0.001). This benefit was observed across all patient subgroups, including those based on the β(2)-microglobulin level, cytogenetic profile, and response after transplantation. With a median follow-up period of 45 months, more than 70% of patients in both groups were alive at 4 years. The rates of grade 3 or 4 peripheral neuropathy were similar in the two groups. The incidence of second primary cancers was 3.1 per 100 patient-years in the lenalidomide group versus 1.2 per 100 patient-years in the placebo group (P=0.002). Median event-free survival (with events that included second primary cancers) was significantly improved with lenalidomide (40 months, vs. 23 months with placebo; P<0.001). CONCLUSIONS: Lenalidomide maintenance after transplantation significantly prolonged progression-free and event-free survival among patients with multiple myeloma. Four years after randomization, overall survival was similar in the two study groups. (Funded by the Programme Hospitalier de Recherche Clinique and others; ClinicalTrials.gov number, NCT00430365.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1114138

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citation
A note on quantifying follow-up in studies of failure time
SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Self-citation
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
A PROSPECTIVE, RANDOMIZED TRIAL OF AUTOLOGOUS BONE MARROW TRANSPLANTATION AND CHEMOTHERAPY IN MULTIPLE MYELOMA
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citation
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984
Self-citation

Flagged first, then by citations

Show all 24 references

Sorted by citations

Items 101–200 of 1,000

Maintenance Treatment and Survival in Patients With Myeloma
Gay, F., Jackson, G. H., Rosiñol, L., Holstein, S. A., Moreau, P., Spada, S., Davies, F. E., Lahuerta, J. J., Leleu, X. P., Bringhen, S., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2961 · Cited by 94
Self-citation
Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time
Kumar, S. K., Dispenzieri, A. A., Fraser, R. A., Fei, M., Akpek, G., Cornell, R. F., Kharfan‐Dabaja, M. A., Freytes, C. O., Hashmi, S. K., Hildebrandt, G. C., et al. (2017) · Leukemia · doi:10.1038/leu.2017.331 · Cited by 92
Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies
Jadlowsky, J. K., Hexner, E. O., Marshall, A., Grupp, S. A., Frey, N. V., Riley, J. L., Veloso, E. A., McConville, H., Rogal, W., Czuczman, C., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03478-6 · Cited by 91
How I treat high-risk myeloma
Lonial, S., Boise, L., & Kaufman, J. L. (2015) · Blood · doi:10.1182/blood-2015-06-653261 · Cited by 88
Smoldering multiple myeloma requiring treatment: time for a new definition?
Dispenzieri, A. A., Stewart, A. K., Chanan-Khan, A. A., Rajkumar, S. V., Kyle, R. A., Fonseca, R., Kapoor, P., Bergsagel, P. L., McCurdy, A. B. R., Gertz, M. A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-520890 · Cited by 83
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial
Dytfeld, D., Wróbel, T., Jamroziak, K., Kubicki, T., Robak, P. J., Walter‐Croneck, A., Czyż, J., Tyczyńska, A., Druzd‐Sitek, A., Giannopoulos, K., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00738-0 · Cited by 83
Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.
Dispenzieri, A., Seenithamby, K., Lacy, M., Kumar, S. K., Buadi, F., Hayman, S., Dingli, D., Litzow, M., Gastineau, D., Inwards, D., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.53 · Cited by 82
Solubility parameter of lenalidomide for predicting the type of solubility profile and application of thermodynamic model
Yang, Z., Shao, D., & Zhou, G. (2018) · The Journal of Chemical Thermodynamics · doi:10.1016/j.jct.2018.12.035 · Cited by 81
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients
Jones, J. R., Weinhold, N., Ashby, C., Walker, B. A., Wardell, C. P., Pawlyn, C., Rasche, L., Melchor, L., Cairns, D. A., Gregory, W. M., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.202200 · Cited by 85
Next-generation multiple myeloma treatment: a pharmacoeconomic perspective
Rajkumar, S. V., & Harousseau, J. L. (2016) · Blood · doi:10.1182/blood-2016-09-692947 · Cited by 80
Self-citation
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results
Gay, F., Magarotto, V., Crippa, C., Pescosta, N., Guglielmelli, T., Cavallo, F., Pezzatti, S., Ferrari, S., Liberati, A. M., Oliva, S., et al. (2013) · Blood · doi:10.1182/blood-2013-02-483073 · Cited by 80
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
Jones, J. R., Cairns, D. A., Gregory, W. M., Collett, C., Pawlyn, C., Sigsworth, R., Striha, A., Henderson, R., Kaiser, M., Jenner, M. W., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.114 · Cited by 81
Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective
Saraceni, F., Shem‐Tov, N., Olivieri, A., & Nagler, A. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.330 · Cited by 79
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
Moreau, P., Joshua, D. E., Chng, W.-J., Palumbo, A. P., Goldschmidt, H., Hájek, R., Facon, T. T. F., Ludwig, H., Pour, L., Niesvizky, R., et al. (2016) · Leukemia · doi:10.1038/leu.2016.186 · Cited by 77
Self-citation
The application and biology of immunomodulatory drugs (IMiDs) in cancer
Pan, B., & Lentzsch, S. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.004 · Cited by 76
Second primary malignancies in multiple myeloma: A review
Poh, C., Keegan, T. H. M., & Rosenberg, A. S. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100757 · Cited by 75
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance
Usmani, S. Z., Sexton, R. E., Hoering, A., Heuck, C. J., Nair, B. P., Waheed, S., Alsayed, Y. M., Chauhan, N., Ahmad, N., Atrash, S., et al. (2012) · Blood · doi:10.1182/blood-2012-04-421883 · Cited by 75
Multiple Myeloma, Version 2.2016
Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C. L., Djulbegović, B., Fung, H. C. H., Gasparetto, C., Godby, K. N., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0167 · Cited by 75
Current approaches to management of newly diagnosed multiple myeloma
Goel, U., Usmani, S. Z., & Kumar, S. K. (2022) · American Journal of Hematology · doi:10.1002/ajh.26512 · Cited by 76
Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma
Lemieux‐Blanchard, É., Hulin, C., Caillot, D., Tardy, S., Dorvaux, V., Michel, J., Gastinne, T., Rossi, C., Legouge, C., Touzeau, C., et al. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.11.013 · Cited by 72
Self-citation
Clinical value of molecular subtyping multiple myeloma using gene expression profiling
Weinhold, N., Heuck, C. J., Rosenthal, A., Thanendrarajan, S., Epstein, J., van Rhee, F., Zangari, M., Hoering, A., Tian, E., Davies, F. E., et al. (2015) · Leukemia · doi:10.1038/leu.2015.309 · Cited by 71
Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics
Razavi, P., Rand, K. A., Cozen, W., Chanan-Khan, A. A., Usmani, S. Z., & Ailawadhi, S. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.19 · Cited by 71
Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools
Fotiou, D., Gavriatopoulou, M., & Terpos, E. (2020) · Cancers · doi:10.3390/cancers12010191 · Cited by 69
Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party
Sobh, M. A. K., Michallet, M., Gahrton, G., Iacobelli, S., van Biezen, A., Schönland, S. O., Petersen, E. J., Schaap, N. P., Bonifazi, F., Volin, L., et al. (2016) · Leukemia · doi:10.1038/leu.2016.101 · Cited by 69
Self-citation
Guidelines for screening and management of late and long‐term consequences of myeloma and its treatment
Snowden, J. A., Greenfield, D., Bird, J. M., Boland, E. G., Bowcock, S. J., Fisher, A., Low, E., Morris, M., Yong, K., Pratt, G., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14514 · Cited by 69
Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial
Rosiñol, L., Oriol, A., Teruel, A. I., de la Guía, A. L., Blanchard, M., de la Rubia, J., Granell, M., Sampol, M., Palomera, L., González, Y., et al. (2017) · Leukemia · doi:10.1038/leu.2017.35 · Cited by 69
Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs
Pittari, G., Vago, L., Festuccia, M. B., Bonini, C., Mudawi, D., Giaccone, L., & Bruno, B. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01444 · Cited by 73
Thalidomide and its analogues in the treatment of Multiple Myeloma
Latif, T., Chauhan, N., Khan, R. Z., Moran, A. E., & Usmani, S. Z. (2012) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-1-27 · Cited by 70
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis
Palladini, G. O., Russo, P., Milani, P., Foli, A., Lavatelli, F., Nuvolone, M., Perlini, S., & Merlini, G. (2012) · Haematologica · doi:10.3324/haematol.2012.073593 · Cited by 68
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
Moreau, P., Zamagni, E., & Mateos, M. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0200-1 · Cited by 68
Self-citation
Current strategies for treatment of relapsed/refractory multiple myeloma
Laubach, J. P., Voorhees, P. M., Hassoun, H., Jakubowiak, A. J., Lonial, S., & Richardson, P. G. G. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.882764 · Cited by 68
Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations
Greco, R., Ruggeri, A., McLornan, D. P., Snowden, J. A., Alexander, T., Angelucci, E., Averbuch, D., Bazarbachi, A. A., Hazenberg, M. D., Kałwak, K., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02701-3 · Cited by 69
Therapeutic Advancements in Multiple Myeloma
Gozzetti, A., Candi, V., Papini, G., & Bocchia, M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00241 · Cited by 67
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial
Goldschmidt, H., Mai, E. K., Dürig, J., Scheid, C., Weisel, K. C., Kunz, C., Bertsch, U., Hielscher, T., Merz, M., Munder, M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0724-1 · Cited by 67
How I treat first relapse of myeloma
Harousseau, J. L., & Attal, M. (2017) · Blood · doi:10.1182/blood-2017-03-726703 · Cited by 67
Self-citation
What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone?
Zhao, H., Huang, X., Gao, X., Cai, H., Zhang, L., Feng, J., Cao, X., Zhou, D., & Li, J. (2019) · Leukemia · doi:10.1038/s41375-019-0391-2 · Cited by 66
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma
Rosiñol, L., Oriol, A., Ríos, R., Blanchard, M. J., Jarque, I., Bargay, J., Hernández, M. T., Cabañas, V., Carrillo‐Cruz, E., Sureda, A. M., et al. (2023) · Blood · doi:10.1182/blood.2022019531 · Cited by 66
Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers
Mohty, M., & Harousseau, J. (2014) · Haematologica · doi:10.3324/haematol.2013.096149 · Cited by 66
Self-citation
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report
Morton, L. M., Saber, W., Baker, K. S., Barrett, A. J., Bhatia, S., Engels, E. A., Gadalla, S. M., Kleiner, D. E., Pavletic, S. Z., & Burns, L. J. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.09.005 · Cited by 68
Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis
Mahindra, A. K., Hari, P., Fraser, R. A., Fei, M., Huang, J., Berdeja, J. G., Callander, N. S., Costa, L. J., Díaz, M. Á., Freytes, C. O., et al. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.198 · Cited by 65
Multiple myeloma: Role of autologous transplantation
Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101929 · Cited by 68
Defining and treating high-risk multiple myeloma
Usmani, S. Z., Rodríguez‐Otero, P., Bhutani, M., Mateos, M., & Miguel, J. F. S. (2015) · Leukemia · doi:10.1038/leu.2015.209 · Cited by 64
Infection risk with immunomodulatory and proteasome inhibitor–based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis
Teh, B. W., Harrison, S. J., Worth, L. J., Thursky, K., & Slavin, M. A. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.07.025 · Cited by 64
Clinical Cancer Advances 2012: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
Roth, B. J., Krilov, L., Adams, S., Aghajanian, C. A., Bach, P. B., Braiteh, F., Brose, M. S., Ellis, L. M., Erba, H. P., George, D. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.1938 · Cited by 63
Single versus tandem high‐dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long‐term results from the phase III GMMG ‐ HD 2 trial
Mai, E. K., Benner, A., Bertsch, U., Brossart, P., Hänel, A., Kunzmann, V., Naumann, R., Neben, K., Egerer, G., Ho, A. D., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13994 · Cited by 67
Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance
Palazzo, M. A., Shah, G. L., Copelan, O. R., Seier, K. P., Devlin, S. M., Maloy, M., Kenny, S., Hassoun, H., Korde, N., Lendvai, N. K., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.12.795 · Cited by 63
Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients
Busch, A., Zeh, D., Janzen, V., Mügge, L.-O., Wolf, D. G. F., Fingerhut, L., Hahn‐Ast, C., Maurer, O., Brossart, P., & von Lilienfeld‐Toal, M. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12343 · Cited by 62
Observational study of multiple myeloma in Latin America
On behalf of the International Myeloma Working Group Latin America, Hungria, V., Maiolino, Â., Martınez, G., Duarte, G. O., Bittencourt, R., Peters, L. G. B., Colleoni, G. W. B., de Oliveira, L. C. O., Crusoé, E. D. Q., et al. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2866-9 · Cited by 62
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE
Goldschmidt, H., Baertsch, M., Schlenzka, J., Becker, N., Habermehl, C., Hielscher, T., Raab, M., Hillengaß, J., Sauer, S., Müller‐Tidow, C., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0948-0 · Cited by 63
Gene expression profile alone is inadequate in predicting complete response in multiple myeloma
Amin, S. B., Yip, W.-K., Minvielle, S., Broyl, A., Li, Y., Hanlon, B. M., Swanson, D. M., Shah, P. K., Moreau, P., van der Holt, B., et al. (2014) · Leukemia · doi:10.1038/leu.2014.140 · Cited by 61
Self-citation
Ixazomib for the treatment of multiple myeloma
Richardson, P. G. G., Zweegman, S., O’Donnell, E., Laubach, J. P., Raje, N. S., Voorhees, P. M., Ferrari, R. H., Skácel, T., Kumar, S. K., & Lonial, S. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1528229 · Cited by 61
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
Offidani, M., Corvatta, L., Maracci, L., Liberati, A. M., Ballanti, S., Attolico, I., Caraffa, P., Alesiani, F., di Toritto, T. C., Gentili, S., et al. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.58 · Cited by 62
Trial Watch: Lenalidomide-based immunochemotherapy
Semeraro, M., Vacchelli, E., Eggermont, A. M. M., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.26494 · Cited by 61
Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma
Kaufman, G. P., Gertz, M. A., Dispenzieri, A. A., Lacy, M. Q., Buadi, F. K., Dingli, D., Hayman, S. R., Kapoor, P., Lust, J. A., Russell, S. J., et al. (2015) · Leukemia · doi:10.1038/leu.2015.287 · Cited by 61
Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression‐free survival in multiple myeloma
Maiolino, Â., Hungria, V., Garnica, M., Oliveira-Duarte, G. B., de Oliveira, L. C. O., Mercante, D., MIRANDA, E. C. M., Quero, A. A., Peres, A. L., Barros, J. C., et al. (2012) · American Journal of Hematology · doi:10.1002/ajh.23274 · Cited by 59
Allogeneic stem cell transplantation for multiple myeloma: is there a future?
Dhakal, B., Vesole, D. H., & Hari, P. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.325 · Cited by 61
Update on the role of lenalidomide in patients with multiple myeloma
Holstein, S. A., Suman, V. J., & McCarthy, P. L. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718775629 · Cited by 59
Perspectives on the Treatment of Multiple Myeloma
Rafae, A., van Rhee, F., & Hadidi, S. A. (2023) · The Oncologist · doi:10.1093/oncolo/oyad306 · Cited by 65
Phase I/ II study exploring ImMucin, a pan‐major histocompatibility complex, anti‐ MUC 1 signal peptide vaccine, in multiple myeloma patients
Carmon, L., Avivi, I. M., Kovjazin, R., Zuckerman, T., Dray, L., Gatt, M. E., Or, R., & Shapira, M. Y. (2014) · British Journal of Haematology · doi:10.1111/bjh.13245 · Cited by 58
An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma
Offidani, M., Corvatta, L., Caraffa, P., Gentili, S., Maracci, L., & Leoni, P. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s49187 · Cited by 58
Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline
Sive, J. I., Cuthill, K., Hunter, H. M., Kazmi, M. A., Pratt, G., Smith, D., & British Society of Haematology (2021) · British Journal of Haematology · doi:10.1111/bjh.17410 · Cited by 62
Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients
Roeker, L. E., Larson, D. R., Kyle, R. A., Kumar, S. K., Dispenzieri, A. A., & Rajkumar, S. V. (2013) · Leukemia · doi:10.1038/leu.2013.34 · Cited by 56
Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy
Dima, D., Dower, J., Comenzo, R. L., & Varga, C. (2020) · Cancer Management and Research · doi:10.2147/cmar.s212526 · Cited by 56
Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics
Chakraborty, R., Muchtar, E., Kumar, S. K., Jevremović, D., Buadi, F. K., Dingli, D., Dispenzieri, A. A., Hayman, S. R., Hogan, W. J., Kapoor, P., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.01.076 · Cited by 55
Experimental analysis and thermodynamic modelling of lenalidomide solubility in supercritical carbon dioxide
Sajadian, S. A., Amani, M., Ardestani, N. S., & Shirazian, S. (2022) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2022.103821 · Cited by 55
Treatment for patients with newly diagnosed multiple myeloma in 2015
Mateos, M., Ocio, E. M., Paiva, B., Rosiñol, L., Martínez‐López, J., Bladé, J., Lahuerta, J. J., García‐Sánz, R., & Miguel, J. F. S. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.06.001 · Cited by 55
Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years
Engelhardt, M. M., Ihorst, G., Landgren, O., Pantić, M., Reinhardt, H., Waldschmidt, J. M., May, A. M., Schumacher, M. C., Kleber, M., & Wäsch, R. (2015) · Haematologica · doi:10.3324/haematol.2015.127548 · Cited by 55
Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review
Wang, Y., Yang, F., Shen, Y., Zhang, W., Wang, J., Chang, V. T.-S., Andersson, B. S., Qazilbash, M. H., Champlin, R. E., Berenson, J. R., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv342 · Cited by 57
Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options
Ramasamy, K., Gay, F., Weisel, K. C., Zweegman, S., Mateos, M., & Richardson, P. G. G. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100808 · Cited by 55
Ixazomib for the treatment of multiple myeloma
Gentile, M., Offidani, M., Vigna, E., Corvatta, L., Recchia, A. G., Morabito, L., Morabito, F., & Gentili, S. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1065250 · Cited by 53
Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities
Guha, A., Armanious, M. A., & Fradley, M. G. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.06.001 · Cited by 54
Lenalidomide Treatment for Multiple Myeloma: Systematic Review and Meta-Analysis of Randomized Controlled Trials
Yang, B. Y., Yu, R., Chi, X.-H., & Lu, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064354 · Cited by 52
Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma
Leleu, X. P., Fouquet, G., Hébraud, B., Roussel, M., Caillot, D., Chrétien, M., Arnulf, B., Szalat, R. E., Garderet, L., Benajiba, L., et al. (2013) · Leukemia · doi:10.1038/leu.2013.101 · Cited by 52
Self-citation
Multiple Myeloma: An Update
Al‐Farsi, K. (2013) · Oman Medical Journal · doi:10.5001/omj.2013.02 · Cited by 53
FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
Pulte, E. D., Dmytrijuk, A., Nie, L., Goldberg, K. B., McKee, A. E., Farrell, A. T., & Pazdur, R. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0440 · Cited by 52
Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma
Alonso, R., Cedena, M., Gómez‐Grande, A., Ríos, R., Moraleda, J. M., Cabañas, V., Moreno, M. J., López‐Jiménez, J., Martín‐Moro, F., Sanz, A., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25507 · Cited by 52
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma
Miguel, J. F. S., Weisel, K. C., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Moreau, P., Baños, A., Oriol, A., Garderet, L., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.125864 · Cited by 51
Self-citation
Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics
Chhabra, S. (2017) · Pharmaceuticals · doi:10.3390/ph10020040 · Cited by 52
Long‐term Outcomes in Patients With Multiple Myeloma
Verelst, S. G. R., Blommestein, H. M., de Groot, S., Gonzalez‐McQuire, S., DeCosta, L., de Raad, J. B., Groot, C. A. U., & Sonneveld, P. (2018) · HemaSphere · doi:10.1097/hs9.0000000000000045 · Cited by 53
Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing
Kumar, S. K., Buadi, F. K., & Rajkumar, S. V. (2018) · Blood · doi:10.1182/blood-2018-08-825349 · Cited by 51
Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel
Stefano, V. D., Larocca, A., Carpenedo, M., Cavo, M., Raimondo, F. D., Falanga, A., Offidani, M., Petrucci, M. T., Ruggeri, M., Santi, R. M., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.280893 · Cited by 52
The future of autologous stem cell transplantation in myeloma
van Rhee, F., Giralt, S., & Barlogie, B. (2014) · Blood · doi:10.1182/blood-2014-03-561985 · Cited by 50
Subsequent Malignant Neoplasms after Hematopoietic Cell Transplantation
Socié, G., Baker, K. S., & Bhatia, R. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.10.005 · Cited by 51
Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation
Çetin, A. E., Stevens, M. M., Calistri, N. L., Fulciniti, M., Olçum, S., Kimmerling, R. J., Munshi, N. C., & Manalis, S. R. (2017) · Nature Communications · doi:10.1038/s41467-017-01593-2 · Cited by 54
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial
Oliva, S., Bruinink, D. H. O., Říhová, L., D’Agostino, M., Pantani, L., Capra, A., van der Holt, B., Troia, R., Petrucci, M. T., Villanova, T., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00498-0 · Cited by 50
Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis
Saleem, K., Franz, J. K., Klem, M. L., Yabes, J. G., Boyiadzis, M. M., Jones, J. R., Shaikh, N., & Lontos, K. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00289-7 · Cited by 50
Analysis of long‐term survival in multiple myeloma after first‐line autologous stem cell transplantation: impact of clinical risk factors and sustained response
Lehners, N., Becker, N., Benner, A., Pritsch, M., Löpprich, M., Mai, E. K., Hillengaß, J., Goldschmidt, H., & Raab, M. S. (2017) · Cancer Medicine · doi:10.1002/cam4.1283 · Cited by 48
Second malignancies in multiple myeloma; emerging patterns and future directions
Maclachlan, K. H., Diamond, B. T., Maura, F., Hillengaß, J., Turesson, I., Landgren, O., & Kazandjian, D. G. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101144 · Cited by 48
Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: a population-based cohort study
Bilmon, I., Ashton, L. J., Marsney, R. E. L., Dodds, A. J., O'Brien, T. A., Wilcox, L., Nivison‐Smith, I., Daniels, B. J., Vajdic, C. M., CAST study group, et al. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.13 · Cited by 47
New Cancers after Autotransplantations for Multiple Myeloma
Mahindra, A. K., Raval, G. G., Mehta, P., Brazauskas, R., Zhang, M., Zhong, X., Bird, J. M., Freytes, C. O., Hale, G. A., Herzig, R. H., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.12.028 · Cited by 47
Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein–Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression
Jones, R. J., Iempridee, T., Wang, X., Lee, H. C., Mertz, J. E., Kenney, S. C., Lin, H. C., Baladandayuthapani, V., Dawson, W. O., Shah, J. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2242 · Cited by 48
Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis
Li, Y., YinHui, T., Yunliang, Z., & Sun, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16235 · Cited by 47
Secondary Primary Malignancies in Multiple Myeloma: An Old Nemesis Revisited
Yang, J., Terebelo, H. R., & Zonder, J. A. (2012) · Advances in Hematology · doi:10.1155/2012/801495 · Cited by 47
Characteristics and Outcomes of Patients With Multiple Myeloma Who Develop Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Pemmaraju, N., Shah, D., Kantarjian, H. M., Orlowski, R. Z., Nogueras‐González, G. M., Baladandayuthapani, V., Jain, N., Wagner, V., Garcia‐Manero, G., Shah, J. J., et al. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.07.001 · Cited by 47
IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM)
Krönke, J., Kuchenbauer, F., Kull, M., Teleanu, V, Bullinger, L., Bunjes, D., Greiner, A., Kolmus, S., Köpff, S., Schreder, M., et al. (2017) · Leukemia · doi:10.1038/leu.2016.384 · Cited by 46
Immunomodulatory drugs in multiple myeloma
Andhavarapu, S., & Roy, V. (2013) · Expert Review of Hematology · doi:10.1586/ehm.12.62 · Cited by 47
Lenalidomide long-term neurotoxicity
Torre, C. D., Zambello, R., Cacciavillani, M., Campagnolo, M., Berno, T., Salvalaggio, A., March, E. D., Barilà, G., Lico, A., Lucchetta, M., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003093 · Cited by 46
Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
Dimopoulos, M. A., Wang, M. L., Maisnar, V., Minařík, J., Bensinger, W., Mateos, M., Obreja, M., Blædel, J., & Moreau, P. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0583-7 · Cited by 46
Self-citation
Immunotherapy in Multiple Myeloma
Soekojo, C. Y., Ooi, M. G. M., Mel, S. D., & Chng, W. J. (2020) · Cells · doi:10.3390/cells9030601 · Cited by 48
Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry
Abonour, R., Wagner, L. I., Durie, B. G. M., Jagannath, S., Narang, M., Terebelo, H. R., Gasparetto, C., TOOMEY, K. E., Hardin, J. W., Kitali, A., et al. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3446-y · Cited by 45

Authors: Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., Decaux, O., Leyvraz, S., Vekemans, M.-C., Voillat, L., Michallet, M., Pegourie, B., Dumontet, C., Roussel, M., Leleu, X., Mathiot, C., Payen, C., Avet-Loiseau, H., & Harousseau, J.-L.
Affiliations: Hôpital Purpan (FR)
CHU Dijon Bourgogne (FR)
Hôpital Claude Huriez (FR)
Institut Paoli-Calmettes (FR)
Centre Hospitalier Régional et Universitaire de Nancy (FR)
Hôpital Saint-Antoine (FR)
Hôpital Pontchaillou (FR)
Centre Hospitalier Universitaire Vaudois (CH)
Centre Hospitalier Universitaire de Besançon (FR)
Hôpital Edouard Herriot (FR)
Institut Curie (FR)
ORCID: Attal, Michel
Caillot, Denis
Moreau, Philippe
Facon, Thierry
Hulin, Cyrille
Garderet, Laurent
Decaux, Olivier
Leyvraz, Serge
Vekemans, Marie-Christiane
Michallet, Mauricette
Dumontet, Charles
Roussel, Murielle
Leleu, Xavier
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2012-05-10
Volume: 366
Issue: 19
Pages: 1782-1791
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1114138
OpenAlex: W2128084036
Semantic Scholar: c28c0ef900dcfd0347dbf26ecd97d5547f948a9a
Cited by: 1,155
References: 24
Citations by year: 2026: 32 · 2025: 36 · 2024: 43 · 2023: 61 · 2022: 70 · 2021: 85 · 2020: 79 · 2019: 68 · 2018: 83 · 2017: 98 · 2016: 108 · 2015: 86 · 2014: 102 · 2013: 133 · 2012: 68
FWCI: 82.78
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Digital Access to Libraries (submittedVersion)
Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
IRIS (submittedVersion)
SERVAL (Université de Lausanne) (submittedVersion)
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Health Sciences › Medicine › Oncology › Bone health and treatments
Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Keywords: lenalidomide, maintenance therapy, multiple myeloma, autologous stem cell transplantation, progression-free survival, event-free survival, secondary malignancies, peripheral neuropathy, young patients, residual disease
MeSH terms: Lenalidomide, Adult, Aged, Antineoplastic Agents, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Myeloma, Thalidomide, Neoplasms, Second Primary, Disease-Free Survival, Stem Cell Transplantation, Kaplan-Meier Estimate, Young Adult, Maintenance Chemotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks